INVESTMENTS
Bellerive Capital invests exclusively in projects
whose potential we believe in ourselves.
Investing our own capital and taking an active board role.
The following investments illustrate our approach:
Lumendi AG
Medical technology | Switzerland | active investment
Lumendi AG is a Swiss medical technology company developing innovative solutions for minimally invasive colonoscopy. At its core is the DiLumen system — an intraluminal intervention device that significantly improves manoeuvrability and control during endoscopic procedures in the colon, making complex procedures safer and more efficient.
Lumendi addresses a significant clinical need: conventional endoscopy often has limitations when removing large or hard-to-reach polyps. The DiLumen system substantially expands endoscopists’ capabilities, with the aim of avoiding open surgery and improving patient safety.
Through Denis Savuk’s role as a member of the board of directors, Bellerive Capital is actively involved in Lumendi’s strategic development — particularly in corporate finance, investor relations and international business development.
Further information: lumendi.com
Advanced Microbiotics AG
Life Sciences | Switzerland | active investment
Advanced Microbiotics AG (AMB) is a Swiss biotechnology company specialising in microbiome research.
The company develops microbiome-based solutions with therapeutic potential.
Bellerive Capital supports AMB as a strategic partner and investor.
Further information: amb-ag.com